Meta Glasses for Low Vision

NCT07317180 | Not Yet Recruiting

• 1 other identifier: 128336
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Visual impairment, particularly from glaucoma and retinal dystrophies, significantly hinders mobility and increases the risk of falls, leading to decreased independence and mental health challenges. Current low-vision assistive technologies primarily focus on near-task magnification for reading, leaving a critical gap in tools designed to assist with real-world navigation and peripheral vision loss. To address this, the proposed research evaluates Meta AI glasses, which offer real-time scene narration and object recognition, integrated with the Be My Eyes network. The study hypothesizes that this wearable AI technology will improve ambulation, orientation, and overall quality of life for patients, providing a functional solution for mobility that traditional devices lack.

Conditions

Irreversible Vision Loss

Outcome Measures

Primary Outcomes (1)

• patient-reported vision-targeted quality of life

  The primary outcome will be change in patient-reported vision-targeted quality of life, measured using the National Eye Institute Visual Function Questionnaire - 25 item (NEI VFQ-25).

  4 weeks

Study Arms (2)

Meta AI Glasses

EXPERIMENTAL

25 Patients receiving standard care for their eye condition will be provided with customized Meta AI Glasses integrated with the Be My Eyes network. Each patient will receive training on device use, followed by an adaptation period where they incorporate the glasses into their daily activities.

Other: Meta AI Glasses

Control

SHAM COMPARATOR

Control group: 25 Patients will continue receiving standard care and will not receive the Meta AI glasses during the study period.

Other: Control

Interventions

Meta AI Glasses OTHER

Meta AI glasses in patients with low vision

Meta AI Glasses

Control OTHER

25 Patients will continue receiving standard care and will not receive the Meta AI glasses during the study period.

Control

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Confirmed diagnosis of glaucoma, retinal dystrophy, or another condition associated with legal blindness.
• Presence of documented irreversible vision loss
• No surgical or laser procedures in the last 6 months
• Visual field worse than 12db or poor visual acuity 20/400 or worse

You may not qualify if:

• Has no access to telephone
• Unable to speak English
• Has previously received comprehensive low vision services
• \. Has history of stroke with aphasia 6. Has other health condition that would preclude follow-up (e.g., significant malignancy or life-threatening disease) 7. Is unable or unwilling to attend clinic visits required for the study 8. Reports significant loss of vision since last eye exam

Sponsors & Collaborators

• London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's: lead

Central Study Contacts

Monali Malvankar

CONTACT

519-685-8500; mmalvan@uwo.ca

Cindy Hutnik

CONTACT

519-646-6100; Cindy.Hutnik@sjhc.london.on.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: December 19, 2025
• First Posted: January 5, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: January 5, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share